During the last session, Mainz Biomed N.V (NASDAQ:MYNZ)’s traded shares were 4.71 million, with the beta value of the company hitting 0.07. At the end of the trading day, the stock’s price was $0.21, reflecting an intraday loss of -5.18% or -$0.01. The 52-week high for the MYNZ share is $1.79, that puts it down -752.38 from that peak though still a striking 9.52% gain since the share price plummeted to a 52-week low of $0.19. The company’s market capitalization is $12.35M, and the average intraday trading volume over the past 10 days was 8.24 million shares, and the average trade volume was 3.22 million shares over the past three months.
Mainz Biomed N.V (NASDAQ:MYNZ) trade information
Mainz Biomed N.V (MYNZ) registered a -5.18% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.18% in intraday trading to $0.21, hitting a weekly high. The stock’s 5-day price performance is -15.04%, and it has moved by -26.76% in 30 days. Based on these gigs, the overall price performance for the year is -81.53%. The short interest in Mainz Biomed N.V (NASDAQ:MYNZ) is 1.52 million shares and it means that shorts have 0.61 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mainz Biomed N.V (MYNZ) estimates and forecasts
Statistics show that Mainz Biomed N.V has outperformed its competitors in share price, compared to the industry in which it operates. Mainz Biomed N.V (MYNZ) shares have gone down -62.26% during the last six months, with a year-to-date growth rate more than the industry average at 45.68% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 44.44% this quarter and then jump 59.82% in the quarter after that. In the rating firms’ projections, revenue will increase 34.01% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 225k as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 300k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 250.1k and 248.95k respectively. In this case, analysts expect current quarter sales to shrink by -10.04% and then jump by 20.51% in the coming quarter.
MYNZ Dividends
Mainz Biomed N.V is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 25000.0 shares, is of VONTOBEL HOLDING LTD.’s that is approximately 0.1181% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $10025.0.
